Mutant p53 blocks SESN1/AMPK/PGC-1 alpha/UCP2 axis increasing mitochondrial O-2-center dot production in cancer cells

BACKGROUND: The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. METHODS: A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were u...

Descripción completa

Detalles Bibliográficos
Autores: Cordani, Marco, Butera, Giovanna, Dando, Ilaria, Torrens-Mas, Margalida, Butturini, Elena, Pacchiana, Raffaella, Oppici, Elisa, Cavallini, Chiara, Gasperini, Sara, Tamassia, Nicola, Nadal-Serrano, Mercedes, Coan, Michela, Rossi, Davide, Gaidano, Gianluca, Caraglia, Michele, Mariotto, Sofia, Spizzo, Riccardo, Roca, Pilar, Oliver, Jordi, Scupoli, Maria Teresa, Donadelli, Massimo
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/9071
Acceso en línea:https://hdl.handle.net/20.500.13003/9071
Access Level:acceso abierto
Palabra clave:Oxygen
Free Radical Scavengers
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
Tumor Suppressor Protein p53
Uncoupling Protein 2
Female
AMP-Activated Protein Kinases
Heat-Shock Proteins
Male
MCF-7 Cells
Neoplasms
Acetylcysteine
Middle Aged
Cell Line, Tumor
Humans
Reactive Oxygen Species
Adult
Mitochondria
Aged
Aged, 80 and over
Mitocondrias
Línea Celular Tumoral
Proteína p53 Supresora de Tumor
Femenino
Proteínas de Choque Térmico
Células MCF-7
Masculino
Acetilcisteína
Humanos
Persona de Mediana Edad
Neoplasias
Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma
Anciano
Proteínas Quinasas Activadas por AMP
Especies Reactivas de Oxígeno
Proteína Desacopladora 2
Anciano de 80 o más Años
Oxígeno
Adulto
Depuradores de Radicales Libres
Descripción
Sumario:BACKGROUND: The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. METHODS: A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. The effects of mutant p53 were evaluated by confocal microscopy, reactive oxygen species production assay, immunoblotting, and quantitative reverse transcription polymerase chain reaction after cellular transfection. RESULTS: We demonstrate that oncogenic mutant p53 isoforms are able to inhibit SESN1 expression and consequently the amount of SESN1/AMPK complex, resulting in the downregulation of the AMPK/PGC-1 alpha/UCP2 axis and mitochondrial O-2(-)center dot production. We also show a correlation between the decrease of reduced thiols with a poorer clinical outcome of CLL patients bearing mutant TP53 gene. The restoration of the mitochondrial uncoupling protein 2 (UCP2) expression, as well as the addition of the radical scavenger N-acetyl-L-cysteine, reversed the oncogenic effects of mutant p53 as cellular hyper-proliferation, antiapoptotic effect, and resistance to drugs. CONCLUSIONS: The inhibition of the SESN1/AMPK/PGC-1 alpha/UCP2 axis contributes to the pro-oxidant and oncogenic effects of mutant p53, suggesting pro-oxidant drugs as a therapeutic approach for cancer patients bearing mutant TP53 gene.